HOUSE_OVERSIGHT_024646.jpg
1.42 MB
Extraction Summary
0
People
6
Organizations
6
Locations
3
Events
3
Relationships
4
Quotes
Document Information
Type:
Investment report page
File Size:
1.42 MB
Summary
This page from an Ackrell Capital report discusses the potential first FDA approval of a cannabis-derived pharmaceutical (Epidiolex) in 2018 and its implications. It also analyzes the commoditization of cannabis flower, noting a downward pricing trend in legalized states like Colorado, Oregon, and Washington, illustrated by a graph of prices from 2016 to 2017.
Organizations (6)
| Name | Type | Context |
|---|---|---|
| Ackrell Capital | ||
| FDA | ||
| GW Pharmaceuticals | ||
| BDS Analytics | ||
| FINRA | ||
| SIPC |
Timeline (3 events)
FDA approval of cannabis-derived pharmaceutical
Submission of NDA for Epidiolex in October 2017
Approval of Sativex in UK in 2010
Locations (6)
| Location | Context |
|---|---|
Relationships (3)
→
→
to
→
→
→
→
Key Quotes (4)
"The FDA’s first-ever approval of a cannabis-derived pharmaceutical may occur in 2018."Source
HOUSE_OVERSIGHT_024646.jpg
Quote #1
"If the FDA approves Epidiolex, such a precedent could be followed by similar approvals in the United States for other cannabis-derived drugs"Source
HOUSE_OVERSIGHT_024646.jpg
Quote #2
"The supply of cannabis in the United States has increased considerably with expanded state legalization."Source
HOUSE_OVERSIGHT_024646.jpg
Quote #3
"examination of the price per gram... reveals a downward trend."Source
HOUSE_OVERSIGHT_024646.jpg
Quote #4
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document